FindMyRecallSubscribe
Class I: serious health riskTerminated

Mylan Pharmaceuticals Insulin Glargine Recall

Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), packaged in a…

Mylan Pharmaceuticals Inc · Morgantown, WV

Risk level
Class I
Reported by FDA
May 4, 2022
Recall ID
D-0845-2022
Check your lot numberHow we source this data

Summary

Mylan Pharmaceuticals recalled Insulin Glargine starting Apr 12, 2022. The FDA classified it as Class I (serious health risk) and published enforcement report D-0845-2022 on May 4, 2022. Reason: Labeling: Missing label on the vial. Status: Terminated.

Why it was recalled

Labeling: Missing label on the vial

Product description

Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), packaged in a 10 mL Multiple-Dose vial inside a carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Manufactured for: Mylan Specialty L.P., Morgantown, WV 26505, NDC 49502-393-80

Lot numbers, UPCs & expiration codes

Lot #: BF21002800, Exp 8/2023

Where it was sold

USA nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0845-2022
Classification
Class I
Status
Terminated
Recall initiated
Apr 12, 2022
FDA report date
May 4, 2022
Quantity
89,665 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Mylan Pharmaceuticals Inc

Original FDA data

Every field from FDA enforcement report D-0845-2022, exactly as published.

Show all FDA fields
City
Morgantown
State
WV
Status
Terminated
Country
United States
Event ID
89970
Address
3711 Collins Ferry Rd
Code information
Lot #: BF21002800, Exp 8/2023
Postal code
26505-2362
Report date
May 4, 2022
Product type
Drugs
Recall number
D-0845-2022
Classification
Class I
Recalling firm
Mylan Pharmaceuticals Inc
Product quantity
89,665 vials
Termination date
Oct 18, 2023
Reason for recall
Labeling: Missing label on the vial
Voluntary / mandated
Voluntary: Firm initiated
Product description
Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), packaged in a 10 mL Multiple-Dose vial inside a carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Manufactured for: Mylan Specialty L.P., Morgantown, WV 26505, NDC 49502-393-80
Distribution pattern
USA nationwide.
Recall initiation date
Apr 12, 2022
Initial firm notification
Press Release
Center classification date
May 4, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0845-2022, published May 4, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls